A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia

Calcified Tissue International

Volumn 79, Issue 3, 2006, Pages 138-144

  Gilfillan, C P ^a   Strauss, B J S ^b   Rodda, C P ^b   Bowden, D K ^b   Kean, A M ^c   Obaid, M ^c   Crawford, B A ^c,d  

^a FRANKSTON HOSPITAL   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d University of Sydney   (Australia)

Author keywords

Bisphosphonate; Osteopenia; Osteoporosis; Thalassemia; Zoledronic acid

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; CALCIUM CARBONATE; CREATININE; DEOXYPYRIDINOLINE; ERGOCALCIFEROL; IBUPROFEN; OSTEOPROTEGERIN; PLACEBO; SOMATOMEDIN C; TESTOSTERONE; ZOLEDRONIC ACID;

ACUTE PHASE RESPONSE; ADULT; AGE; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; BODY HEIGHT; BODY MASS; BODY WEIGHT; BONE DENSITY; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FEVER; FLU LIKE SYNDROME; FRACTURE; GENDER; HIP; HUMAN; LUMBAR SPINE; MALE; MUSCULOSKELETAL PAIN; OSTEOPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ALKALINE PHOSPHATASE; BETA-THALASSEMIA; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMIDAZOLES; MALE;

EID: 33748957343     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-006-0314-x     Document Type: Article

References (24)

1. Voskaridou E, Terpos E (2004) New insights into the pathophysiology and management of osteoporosis in patients with beta thalassemia. Br J Haematol 127:127-139
2. Jensen CE, Tuck SM, Old J, Morris RW, Yardumian A, De Sanctis V, Hoffbrand AV, Wonke B (1997) Incidence of endocrine complications and clinical disease severity related to genotype analysis and iron overload in patients with beta-thalassemia. Eur J Haematol 59:76-81
3. Chapman RW, Hussain MA, Gorman A, Laulicht M, Politis D, Flynn DM, Sherlock S, Hoffbrand AV (1982) Effect of ascorbic acid deficiency on serum ferritin concentration in patients with beta-thalassemia major and iron overload. J Clin Pathol 35:487-91
4. Bekheirnia MR, Abdollah Shamshirsaz A, Kamgar M, Bouzari N, Erfanzadeh G, Pourzahedgilani N, Tabatabaie SM, Abdollah Shamshirsaz A, Kimiagar M, Ezzati F, Larijani B (2004) Serum zinc and its relation to bone mineral density in beta-thalassemic adolescents. Biol Trace Elem Res 97:215-224
5. Lasco A, Morabito N, Gaudio A, Buemi M, Wasniewska M, Frisina N (2001) Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major. Osteoporos Int 12:570-575
6. Rogers MJ (2004) From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif Tissue Int 75:451-461
7. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653-661
8. Aydinok Y, Erermis S, Bukosoglu N, Yilmaz D, Solak V (2005) Psychosocial implications of Thalassemia Major. Pediatr Int 47:84-89
9. Vichinsky EP (1998) The morbidity of bone disease in thalassemia. Ann N Y Acad Sci 850:344-348
10. Anapliotou ML, Kastanias IT, Psara P, Evangelou EA, Liparaki M, Dimitriou P (1995) The contribution of hypogonadism to the development of osteoporosis in thalassemia major: new therapeutic approaches. Clin Endocrinol 42:279-287
11. Carmina E, Di Fede G, Napoli N, Renda G, Vitale G, Lo Pinto C, Bruno D, Malizia R, Rini GB (2004) Hypogonadism and hormone replacement therapy on bone mass of adult women with thalassemia major. Calcif Tissue Int 74:68-71
12. Lasco A, Morabito N, Gaudio A, Crisafulli A, Meo A, Denuzzo G, Frisina N (2002) Osteoporosis and beta-thalassemia major: role of the IGF-I/IGFBP-III axis. J Endocrinol Invest 25:338-344
13. Mahachoklertwattana P, Sirikulchayanonta V, Chuansumrit A, Karnsombat P, Choubtum L, Sriphrapradang A, Domrongkitchaiporn S, Sirisriro R, Rajatanavin R (2003) Bone histomorphometry in children and adolescents with beta-thalassemia disease: iron-associated focal osteomalacia. J Clin Endocrinol Metab 88: 3966-3972
14. Chan YL, Pang LM, Chik KW, Cheng JC, Li CK (2002) Patterns of bone diseases in transfusion-dependent homozygous thalassemia major: predominance of osteoporosis and desferrioxamine-induced bone dysplasia. Pediatr Radiol 32:492-497
15. Voskaridou E, Kyrtsonis MC, Terpos E, Skordili M, Theodoropoulos I, Bergele A, Diamanti E, Kalovidouris A, Loutradi A, Loukopoulos D (2001) Bone resorption is increased in young adults with thalassemia major. Br J Haematol 112:36-41
16. Morabito N, Gaudio A, Lasco A, Atteritano M, Pizzoleo MA, Cincotta M, La Rosa M, Guarino R, Meo A, Frisina N (2004) Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. J Bone Miner Res 19:722-727
17. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83-91
18. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR; Fracture Intervention Trial (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118-4124
19. Morabito N, Lasco A, Gaudio A, Crisafulli A, Di Pietro C, Meo A, Frisina N (2002) Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporos Int 13:644-649
20. Voskaridou E, Terpos E, Spina G, Palermos J, Rahemtulla A, Loutradi A, Loukopoulos D (2003) Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassemia. Br J Haematol 123:730-737
21. Perifanis V, Vyzantiadis T, Vakalopoulou S, Tziomalos K, Garypidou V, Athanassiou-Metaxa M, Harsoulis F (2004) Treatment of beta-thalassemia- associated osteoporosis with zoledronic acid [letter]. Br J Haematol 125:91-92
22. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7:377-387
23. Gilfillan CP, Psihogios V, Strauss BJ, Bowden DK, Rodda CP (1999) Bone mineral density in homozygous β-thalassemia: relationship to anthropometry and gonadal status. Abstract and oral presentation. ANZBMS Annual Scientific Meeting, Cairns, Australia; Aug 14-18
24. Vogiatzi MG, Autio KA, Mait JE, Schneider R, Lesser M, Giardina PJ (2005) Low bone mineral density in adolescents with β-thalassemia. Ann N Y Acad Sci 1054: 462-466